Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,156 active trials54 approved drugs532 evidence items
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06769698 | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 5 | Aug 21, 2026 | clinicaltrials |
| NCT06843551 | The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation(EMPIRE) | recruiting | Phase 2 | 20 | Benjamin SpielerOTHER | 1 | Aug 21, 2026 |
| clinicaltrials |
| NCT07321015 | A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance(Fzp-MA-TNBC) | recruiting | Phase 2 | 72 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07581405 | GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer | not yet recruiting | Phase 2 | 26 | University of Illinois at ChicagoOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07778368 | A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | Shanghai East HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07778732 | Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 32 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 21, 2026 | clinicaltrials |
| NCT03355976 | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | active not recruiting | Phase 2 | 46 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04205968 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | recruiting | Phase 2 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04557449 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors(CDK4i) | active not recruiting | Phase 2 | 362 | PfizerINDUSTRY | 8 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05468697 | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | active not recruiting | Phase 1 / Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT06027268 | Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer(ToPCourT) | active not recruiting | Phase 2 | 36 | Wake Forest University Health SciencesOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06166576 | Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis(RESOLVE) | recruiting | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06178198 | Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma(RESCUE) | recruiting | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06223568 | Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06773845 | Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria(BEAT-UT7) | recruiting | Phase 2 | 100 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06940518 | Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07123090 | A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma(SPARCC) | recruiting | Phase 2 | 25 | Stephanie BergOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07187778 | Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) | recruiting | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07191717 | Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial | recruiting | Phase 2 | 42 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07459673 | HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission | recruiting | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07776717 | TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma(TACTIC-RCC) | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 0 | Aug 20, 2026 | clinicaltrials |
| NCT07777211 | A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 52 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04550494 | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04893109 | ATEMPT 2.0: Adjuvant T-DM1 vs TH | recruiting | Phase 2 | 500 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05142696 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT05361720 | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | recruiting | Phase 2 | 54 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05919108 | Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | recruiting | Phase 2 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06084884 | A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma(ATHENA) | active not recruiting | Phase 1 / Phase 2 | 94 | AstraZenecaINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT06508606 | AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 20 | West China HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07001748 | Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity(STOPGAP II) | recruiting | Phase 2 / Phase 3 | 148 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT07175389 | JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774247 | Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma(AB-TCZ) | not yet recruiting | Phase 2 | 51 | CHA UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04929041 | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative | active not recruiting | Phase 2 / Phase 3 | 427 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06239220 | PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | recruiting | Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06427798 | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | recruiting | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06910072 | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer(UPGRADE-TNBC)(UPGRADE-TNBC) | enrolling by invitation | Phase 2 / Phase 3 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06995508 | Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial | recruiting | Phase 2 | 66 | Roswell Park Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07222657 | Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma | recruiting | Phase 2 | 40 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07544056 | A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 2 / Phase 3 | 446 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT01266642 | Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer | active not recruiting | Phase 2 | 301 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04333537 | Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | recruiting | Phase 2 / Phase 3 | 686 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT05053152 | Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study | active not recruiting | Phase 2 | 194 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05888844 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | active not recruiting | Phase 2 | 63 | Incyte CorporationINDUSTRY | 15 | Aug 17, 2026 | clinicaltrials |
| NCT06095505 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer(ALISCA-Lung1) | recruiting | Phase 2 | 120 | Puma Biotechnology, Inc.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 21, 2026source: clinicaltrials